Gene · 2350
Papers1,286
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,286
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Impaired antigen clearance of macrophages associates with heart failure and non-obstructive azoospermia: insights from transcriptomics, in silico knockout, and in vitro validation. | Front Immunol | 2026 | 42812170 | PubTator, text mining | PubMed |
| Genetic variation in macrophage-restricted FOLR2 is associated with neurodevelopmental and reproductive immune phenotypes. | Front Immunol | 2026 | 42787123 | PubTator, text mining | PubMed |
| Rethinking the Benign Nature of Class II Lupus Nephritis. | bioRxiv | 2026 | 42779877 | PubTator, text mining | PubMed |
| A proinflammatory FOLR2-positive macrophage subtype promotes cutaneous and renal damage in systemic lupus erythematosus. | J Invest Dermatol | 2026 | 42716208 | PubTator, text mining | PubMed |
| Targeting Folate Receptors for the Detection and Selective Treatment of Cancer: Advanced Precision Oncology in Practice. | Int J Biol Sci | 2026 | 42694955 | PubTator, text mining | PubMed |
| Dynamic remodeling of the pancreas immune landscape in obesity. | Nat Commun | 2026 | 42660905 | PubTator, text mining | PubMed |
| The FOLR2-IRF2BP2 axis mediates erythropoiesis impairment by excess folic acid in myelodysplastic neoplasms. | Leukemia | 2026 | 42575953 | PubTator, text mining | PubMed |
| Single-cell transcriptomic profiling of immune microenvironment remodeling in unresectable hepatocellular carcinoma after TACE combined therapies. | Int Immunopharmacol | 2026 | 42480323 | PubTator, text mining | PubMed |
| Folic acid-functionalized PEGylated magnetic nanocarriers for targeted delivery of curcumin to inflamed tissues. | J Pharm Pharmacol | 2026 | 42418839 | PubTator, text mining | PubMed |
| Immune activation induced by FOLR2+ decidual macrophage deficiency impairs decidualization and angiogenesis in spontaneous abortion. | Front Immunol | 2026 | 42416064 | PubTator, text mining | PubMed |
| FOLR2+ tumor-associated macrophages drive metastatic microenvironment remodeling and lymphatic dissemination in colorectal cancer. | Cell Signal | 2026 | 42297063 | PubTator, text mining | PubMed |
| Folate receptor beta targeting of tumor-associated macrophages improves lymphoma cell responses to CD19 CAR T cells. | Hemasphere | 2026 | 42255949 | PubTator, text mining | PubMed |
| High folate receptor expression is associated with aggressive features in prostate cancer with low prostate-specific membrane antigen expression. | BJUI Compass | 2026 | 42255325 | PubTator, text mining | PubMed |
| Exploring current evidence on bispecific CAR-T cell therapy for acute leukemias: a systematic review. | Front Oncol | 2026 | 42109662 | PubTator, text mining | PubMed |
| MORPHEUS-Lung: biomarkers and clinical response to atezolizumab + bevacizumab + stereotactic body radiotherapy in patients with metastatic non-small cell lung cancer. | Lung Cancer | 2026 | 42103553 | PubTator, text mining | PubMed |
| Human peritoneal CCR2LowCRIgHigh macrophage subset exhibits embryonic origin-like phenotypes. | Hum Cell | 2026 | 41991819 | PubTator, text mining | PubMed |
| Proteome-wide reverse molecular docking reveals folate receptor as a mediator of PFAS-induced neurodevelopmental toxicity. | J Hazard Mater | 2026 | 41990651 | PubTator, text mining | PubMed |
| Folate receptor beta drives NLRP3 inflammasome activation and pyroptosis in macrophages independent of folate binding. | J Immunol | 2026 | 41984502 | PubTator, text mining | PubMed |
| E-Cadherin Is an Accurate Target for Fluorescence-Guided Imaging of Lymph Nodes. | Curr Issues Mol Biol | 2026 | 41899420 | PubTator, text mining | PubMed |
| Validation of Folate Receptor-α Selectivity of 6S-5-Methyltetrahydrofolate-Based Radioconjugates: A Prerequisite for Therapeutic Application? | J Nucl Med | 2026 | 41887740 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2350/papers